{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=89",
    "query": {
      "intervention": "Single Dose Placebo",
      "page": 89
    },
    "page_size": 10
  },
  "pagination": {
    "page": 89,
    "page_size": 10,
    "total_count": 4633,
    "total_pages": 464,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=90&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Dose+Placebo&page=88&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T08:46:24.080Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06097663",
      "title": "A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Heart Disease",
        "Clonal Hematopoiesis of Indeterminate Potential (CHIP)"
      ],
      "interventions": [
        {
          "name": "MAS825",
          "type": "DRUG"
        },
        {
          "name": "MAS825 Placebo",
          "type": "DRUG"
        },
        {
          "name": "DFV890",
          "type": "DRUG"
        },
        {
          "name": "DFV890 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 31,
      "start_date": "2024-02-15",
      "completion_date": "2024-11-04",
      "has_results": true,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-11-19T08:46:24.080Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Nashville, Tennessee",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06097663"
    },
    {
      "nct_id": "NCT02075463",
      "title": "Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "Anaemia"
      ],
      "interventions": [
        {
          "name": "GSK1278863",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2014-06-11",
      "completion_date": "2016-03-16",
      "has_results": true,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-11-19T08:46:24.080Z",
      "location_count": 10,
      "location_summary": "Azusa, California • Glendale, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Simi Valley",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02075463"
    },
    {
      "nct_id": "NCT00454116",
      "title": "A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Vandetanib",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2007-03",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2016-10-07",
      "last_synced_at": "2026-11-19T08:46:24.080Z",
      "location_count": 4,
      "location_summary": "Ann Arbor, Michigan • New York, New York • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00454116"
    },
    {
      "nct_id": "NCT02176252",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "AZD1722",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ardelyx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 83,
      "start_date": "2013-07",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2014-06-27",
      "last_synced_at": "2026-11-19T08:46:24.080Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02176252"
    },
    {
      "nct_id": "NCT02367014",
      "title": "Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mitochondrial Myopathy"
      ],
      "interventions": [
        {
          "name": "elamipretide (low dose)",
          "type": "DRUG"
        },
        {
          "name": "elamipretide (intermediate dose)",
          "type": "DRUG"
        },
        {
          "name": "elamipretide (high dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 36,
      "start_date": "2015-02",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2019-12-27",
      "last_synced_at": "2026-11-19T08:46:24.080Z",
      "location_count": 4,
      "location_summary": "San Diego, California • Boston, Massachusetts • Akron, Ohio + 1 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02367014"
    },
    {
      "nct_id": "NCT04542304",
      "title": "Efficacy of Diuretics in Kidney Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Metolazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2021-03-01",
      "completion_date": "2023-06-15",
      "has_results": true,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-11-19T08:46:24.080Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04542304"
    },
    {
      "nct_id": "NCT01862939",
      "title": "A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "DS-7309",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 52,
      "start_date": "2011-04",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-11-19T08:46:24.080Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01862939"
    },
    {
      "nct_id": "NCT05389930",
      "title": "Cannabis' Impact on Alcohol Consumption",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Drinking",
        "Cannabis Use",
        "Cannabis",
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "THC-dominant cannabis",
          "type": "DRUG"
        },
        {
          "name": "CBD-dominant cannabis",
          "type": "DRUG"
        },
        {
          "name": "Cannabis placebo",
          "type": "DRUG"
        },
        {
          "name": "Alcohol",
          "type": "DRUG"
        },
        {
          "name": "Alcohol placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 350,
      "start_date": "2023-03-16",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-19T08:46:24.080Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05389930"
    },
    {
      "nct_id": "NCT01543828",
      "title": "Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD"
      ],
      "interventions": [
        {
          "name": "indacaterol",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2012-01",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2013-05-10",
      "last_synced_at": "2026-11-19T08:46:24.080Z",
      "location_count": 6,
      "location_summary": "Fullerton, California • Saint Charles, Missouri • Charlotte, North Carolina + 3 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01543828"
    },
    {
      "nct_id": "NCT02807675",
      "title": "A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "CVT-301, LIP",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Acorda Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 36,
      "start_date": "2016-06",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-11-19T08:46:24.080Z",
      "location_count": 11,
      "location_summary": "Fountain Valley, California • Boca Raton, Florida • Hallandale, Florida + 8 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02807675"
    }
  ]
}